NAYA Biosciences (NAYA) investor relations material

Executive summary

• Revenue for the six months ended June 30, 2025, was $3.5 million, up from $3.3 million year-over-year, driven by fertility clinic operations and INVOcell device sales.

• Revenue reached $1.86 million in Q2 2025, up 1% year-over-year, setting a new quarterly record.

• Net loss for the six months ended June 30, 2025, was $22.7 million, compared to $3.8 million in the prior year, largely due to non-cash charges from discontinued operations and impairments.

• The company divested an 80.1% stake in NAYA Therapeutics in Q2 2025, returning to a sole focus on fertility services and retaining a 19.9% minority interest.

• Focus shifted exclusively to fertility operations following the NAYA divestiture.

Financial highlights

• Revenue for Q2 2025 was $1.9 million, up from $1.8 million in Q2 2024; cost of revenue increased to $1.1 million from $0.9 million, mainly due to higher labor costs.

• Consolidated clinic revenue increased 1% to $1.83 million year-over-year.

• Operating expenses for the six months ended June 30, 2025, were $7.7 million, up from $6.8 million year-over-year, including a $1.4 million impairment loss.

• Net loss per share from continuing operations was $(7.95), improved from $(22.39) year-over-year.

• Cash as of June 30, 2025, was $0.5 million, down from $0.9 million a year earlier; net cash used in operations was $5.3 million for the first half of 2025.

Outlook and guidance

• The company expects further operational progress in fertility clinics for the remainder of 2025 and is actively pursuing additional profitable IVF clinic acquisitions.

• Management aims to maintain an efficient, scalable structure and pursue accretive revenue opportunities.

• Continued expansion of service offerings, including telehealth and PRP therapy, to drive growth.